The FDA has accepted for review the supplemental biologics license application for Dupixent for the treatment of chronic spontaneous urticaria, Regeneron Pharmaceuticals and Sanofi announced in a press release. The application indicates Dupixent (dupilumab), a fully monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13, for patients aged 12 years and older

Genetic variants related to GERD heightened risks for both asthma and atopic dermatitis by 21%, according to study results published in American Journal of Respiratory and Critical Care Medicine.Further, asthma is a possible risk factor for atopic dermatitis, a causal pathway that has not been identified before, according to researchers.

The FDA has approved tezepelumab-ekko for self-administration in a prefilled, single-use pen among patients aged 12 years and older with severe asthma, according to a press release from the manufacturer. Tezepelumab-ekko (Tezspire; AstraZeneca, Amgen) is the only biologic that has been approved for severe asthma with no phenotype (eg, eosinophilic or allergic) or biomarker limitation within its